PIPELINE WATCH: Three Approvals, Three Filings And Seven Phase III Studies
Executive Summary
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.
You may also be interested in...
Allergan Sees Growth From New Launches, Not Big M&A
Allergan PLC has $27.6m in cash after closing the $40.5bn sale of its generics business to Teva Pharmaceutical Industries Ltd. and paying down $9.3bn debt, but the company will rely on blockbuster sales gains and recent launches for revenue and earnings growth, not a big acquisition.
Novo Nordisk Eyes Residual CV Risk In Atherosclerosis With Ziltivekimab
With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.
GSK Upbeat On RSV Vaccines, Hepatitis B Therapy
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.
Need a specific report? 1000+ reports available
Buy Reports